Modifying therapeutic DNA aptamers to keep them in the bloodstream longer

(Mary Ann Liebert, Inc./Genetic Engineering News) Designing new therapeutic DNA aptamers with diverse side chains can improve their ability to interact with targets, and a new study describes characteristics of these side chains that may determine how long the aptamers remain in the bloodstream.